Oct 28, 2026 · 11 min
European stocks split as banks rise and vaccines falter
Standard Chartered Rises, Stellantis Gains, GSK Falls
The episode captures how earnings strength, costly industrial turnarounds, and weak vaccine demand are reshaping investor attention across Europe.
- 1Standard Chartered beat third-quarter expectations and raised guidance, strengthening the case for European bank resilience.
- 2Stellantis maintained its outlook while pursuing an expensive turnaround amid intensifying competition from Chinese automakers.
- 3GSK shares fell sharply as weak vaccine sales prompted reduced guidance and heightened pressure on its pharmaceutical business.
Don't miss
GSK’s sharp decline after weak vaccine sales and reduced guidance provides the clearest example of how one business weakness can quickly reset market expectations.
The brief
Standard Chartered rose after beating third-quarter expectations and raising guidance, while GSK fell sharply as weak vaccine sales led to reduced guidance.
Stellantis held its outlook but faces a costly turnaround and growing competition from Chinese automakers, making its market story less about stability than execution.
Joshua Gaunt-Warner contributes the European equities perspective, alongside hosts Tiwa Adebayo and Caroline Hepker in the Stock Movers report.
The episode widens its lens with previews of Dubai’s smart-city ambitions and SpaceX’s demanding hiring culture, shaped by Elon Musk’s influence.
Together, the segments connect corporate performance with larger questions about industrial competition, technological growth, and the expectations companies impose on workers.
Books & mentions
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.